- Home
- Equipment
- canada british columbia
- monoclonal primary antibodies
Refine by
Monoclonal Primary Antibodies Equipment Supplied In Canada British Columbia
5 equipment items found
Manufactured by:ImmunoPrecise Antibodies Ltd. based inVictoria, BRITISH COLUMBIA (CANADA)
Our genetic immunization protocols have proven successful in the generation of monoclonal antibodies against new, challenging, and conformation-sensitive targets, and have been successfully applied in transgenic animals. Through our proprietary vectors, our algorithm-based protocols produce native protein with appropriate post-translational modifications in vivo and provide very high transfection ...
Manufactured by:ImmunoPrecise Antibodies Ltd. based inVictoria, BRITISH COLUMBIA (CANADA)
Rapid Prime identifies positive monoclonal antibodies in as little as 32 days. This method is especially beneficial for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. Other sources of immunogens include conserved or smaller proteins, peptides, and whole cell bacteria. After the immunization of rodents, we apply our proprietary ...
Manufactured by:GenomeMe Lab Inc. based inRichmond, BRITISH COLUMBIA (CANADA)
5-methylcytosine (5-mC) is formed from the DNA methylation of the 5-carbon found on the cytosine ring. A 5-methylcytosine monoclonal antibody is a useful tool in identifying and discriminating between the unmodified cytosine base (C) and the methylated cytosine base (5-mC) as part of DNA methylation studies. DNA methylation plays an important role in the repression of transcription in the genome. ...
Manufactured by:Acuitas Therapeutics based inVancouver, BRITISH COLUMBIA (CANADA)
Proteins are the “workhorses” within cells responsible for metabolic processes, transport processes and structural elements. They are coded by genes on DNA and this code is transcribed into a message (messenger RNA or mRNA) within the cell nucleus. This mRNA then leaves the nucleus and is translated into the protein on ribosomes (Figure 1). Therapeutic mRNA is being developed as a new ...
Manufactured by:Augurex Life Sciences Corp. based inVancouver, BRITISH COLUMBIA (CANADA)
In the development of RA and other inflammatory types of arthritis, multiple factors contribute to disease processes to varying degrees in different patients. 14-3-3η is recognized as a new factor within this process and represents a rationale drug target for personalized medicine alongside its 14-3-3η companion biomarker portfolio described above. Augurex preclinical animal studies to ...